Drug intelligence / Profile preview

Microgynon 30

Development stage
Unknown
Lead developer
Bayer
Modality
Small Molecules
Administration
Oral
01

Overview

Microgynon 30 is a combined oral contraceptive pill (COC) used primarily to prevent pregnancy. It contains two active ingredients, ethinylestradiol (an estrogen) and levonorgestrel (a progestogen), in doses of 30 micrograms and 150 micrograms per tablet, respectively. The mechanism of action involves three main effects: inhibition of ovulation by suppressing the release of an egg from the ovaries; thickening of cervical mucus to impede sperm penetration; and alteration of the endometrial lining to reduce the likelihood of implantation. When taken as directed—one tablet daily for 21 days followed by a seven-day break—Microgynon 30 is over 99% effective in clinical trials at preventing pregnancy. Additional benefits may include regulation and reduction in menstrual bleeding, relief from premenstrual symptoms, and decreased menstrual pain[1][2][4][5].

Brand names
Microgynon 30Microgynon30Microgynon-30Microgynon 30 EDMicrogynon30 EDMicrogynon-30 ED
Other names
levonorgestrel and ethinylestradiolethinylestradiol and levonorgestrel
02

Targets

PR (Progesterone receptor)AR (Adrenergic receptors)ER (Estrogen receptor)

Beyond the preview

Go deeper on Microgynon 30.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Microgynon 30.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call